Androgen ablation therapy is the first line treatment for metastatic prostate cancer (PCa). Despite this treatment, PCa will eventually progress to an androgen refractory stage. Although there is no effective therapy for androgen refractory PCa, the androgen receptor (AR) continues to play a role at this stage of the disease. Indeed, at this stage the AR is sensitized to low androgen levels, and can also be activated by non-androgenic factors such as the cytokine, interleukin-6 (IL-6). Several studies, including our own, indicate that de-regulation of AR coregulatory proteins plays an important role in this promiscuous transcriptional activation of the AR. We have shown that, following IL-6 stimulation of PCa cells, components of the MAPK pathway are phosphorylated, thus leading to AR transcriptional activation. We have shown that the coactivator p300 mediates this IL-6-dependent AR transcriptional activation. Our preliminary data also shows that androgens, through the AR, positively regulate expression of the AR. coactivator, FHL2, while negatively regulating expression of the nuclear receptor corepressor, RIP140. Furthermore, we have observed increased FHL2 expression and reduced RIP140 expression in cell-based models of advanced prostate cancer. Our data also suggest that FHL2 plays a role in conjunction with p300 in transcriptionally activating the AR in response to IL-6. We thus hypothesize that the coregulators p300, FHL2, and RIP140 play important roles in AR transcriptional activation during androgen refractory progression of PCa. We suggest that in androgen-dependent PCa, RIP140 forms a complex with the AR, thus limiting the activation of the AR to androgens. However, upon androgen stimulation, or when PCa progresses to an androgen refractory stage, this complex is lost. This de-repression would then allow non-androgenic factors such as IL-6 to induce complex formation between the AR, p300, and FHL2. To test this hypothesis, we propose to (1) determine the role of the p300/FHL2 complex modulated through the MAPK pathway in the IL-6 mediated regulation of the AR;(2) determine the role of RIP140 in the IL-6 mediated regulation of the AR;and (3) determine the role of AR-mediated FHL2 induction and RIP140 repression in androgen dependent and refractory PCa. These studies should enhance our understanding of the mechanisms involved in androgen refractory PCa, and may lead to the identification of new therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA121277-09
Application #
7890630
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2001-09-30
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2012-07-31
Support Year
9
Fiscal Year
2010
Total Cost
$264,063
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
van der Steen, Travis; Tindall, Donald J; Huang, Haojie (2013) Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 14:14833-59
Stanton, Marissa J; Dutta, Samikshan; Zhang, Heyu et al. (2013) Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 73:160-71
Wang, Diping; Lu, Ji; Tindall, Donald J (2013) Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett 335:136-44
Schmidt, Lucy J; Duncan, Kelly; Yadav, Neelu et al. (2012) RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 26:716-35
Jiang, Jingting; Pan, Yunqian; Regan, Kevin M et al. (2012) Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate 72:225-32
Dehm, Scott M; Tindall, Donald J (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183-96
Nacusi, Lucas P; Tindall, Donald J (2011) Targeting 5?-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8:378-84
Lamont, Kristin R; Tindall, Donald J (2011) Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897-907
Huang, Haojie; Tindall, Donald J (2011) Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 1813:1961-4
Heemers, Hannelore V; Schmidt, Lucy J; Sun, Zhifu et al. (2011) Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res 71:1978-88

Showing the most recent 10 out of 31 publications